Abstract The Nuclisome concept builds on a novel twostep targeting strategy with the aim to deliver short-range Auger-electron-emitting radionuclides to nuclear DNA of tumor cells. The concept is based on the use of Nuclisomeparticles, i.e., tumor-targeted PEG-stabilized liposomes loaded with a unique DNA-intercalating compound that enables specific and effective delivery of radionuclides to DNA. The specific and potent two-step targeting leads to eradication of tumor cells while toxicity to normal organs is reduced to a minimum. Results of in vitro and in vivo studies point towards the Nuclisome concept as a promising strategy for the treatment of small tumor masses and, in particular, for the elimination of spread single cells and micrometastases.
Introduction
The efficacy of conventional cancer chemotherapy is often limited by severe side effects that preclude high drug levels from being reached at the tumor site. Targeted drug delivery via liposomes attempts to increase the specificity, and thus minimize the dose-limiting side effects, by encapsulating the cytotoxic agent in liposomes and attaching tumor-specific ligands to the liposome surface. However, despite some progress, the strategy with targeted liposomes loaded with conventional anticancer drugs has so far only had limited success [1, 2] . The Nuclisome concept offers a means to boost the antitumor effect while toxicity to normal tissue is kept low. Thereby, the risk/benefit profile of the drug is significantly improved as compared to that of standard cytotoxic drugs encapsulated in targeted liposomes.
The Nuclisome concept utilizes liposomal carriers in combination with a two-step targeting principle and aims at the delivery of Auger-electron-emitting radionuclides to DNA in the nucleus of tumor cells. The rationale behind the use of Auger-electron-emitting radionuclides is to exploit the biological Auger effect caused by local energy absorption of multiple low-energy electrons to create complex double-strand breaks (DSB) in the DNA [3] . Due to the fact that most of the energy released from Auger electrons is deposited within a small volume of a few cubic nanometers, it is insufficient to target just the tumor cells-the DNA itself needs to be targeted. In fact, to obtain full effect, the radionuclide needs to decay within the DNA molecule either incorporated into the backbone or placed in between the strands [4] . Hence, in order to take advantage of the Auger effect, it is of fundamental importance that the radionuclide be delivered to the nucleus, and furthermore, it is highly desirable that it be guided to a position in very close proximity to DNA (Fig. 1) .
During the last few years, several approaches have been suggested to deliver Auger-emitting radionuclides specifically to tumor cell nuclei. Focus has been on the delivery of 111 In utilizing nuclear localization sequences (NLS) [5] [6] [7] [8] . Proteins or peptides tagged with NLS can be transported from cytoplasmic compartments to the nucleus, and if such proteins or peptides are radiolabeled and targeted to tumor markers, a successful delivery of radionuclides to tumor cell nuclei can potentially be achieved. Encouraging results from studies employing NLS-tagged radiolabeled peptides and proteins verify an increased therapeutic effect compared to that obtained with the corresponding radiolabeled targeting agent lacking NLS [6] . A possible drawback of the NLSbased strategy is the absence of DNA targeting. To take advantage of the so-called Auger effect, close proximity to DNA is required as described above. Utilization of NLS may well induce the redistribution of radionuclides from the cytoplasm to the nucleus but not necessarily to the DNA. Positive charge of NLSs could theoretically enhance the association to DNA, but this still remains to be demonstrated. Recently, an alternative approach for nuclear delivery of Auger-emitting radioiodine based on the use of a polymerbound DNA-intercalating ellipticine derivative was suggested by Sedlacek et al. [9] . The concept opens up for DNA delivery of radionuclides, but depends for its success on a rather complex sequence of events, including the accumulation of the polymer conjugate in tumor tissue due to the enhanced permeation and retention (EPR) effect, nonspecific endocytosis of the conjugate, as well as pH-dependent cleavage of the same conjugate to release the radiolabeled intercalator. Moreover, from the reported data [9] , it is clear that the specific radioactivity of the ellipticine derivative has to be significantly improved in order to achieve therapeutic effect.
In contrast to the strategy suggested by Sedlacek et al. [9] , the Nuclisome concept enables specific targeting of tumor cells and permits efficient and direct delivery of large amounts of radiolabeled compounds to the cells. In the Nuclisome approach, proximity to DNA is achieved by utilizing a specially designed intercalating compound that binds strongly to DNA. After radiolabeling, the DNAbinding compound is loaded into the tumor-targeted liposomes. The liposomes deliver, in a first step, the compound to the tumor cells, and in a second step, the compound guides and delivers the radionuclide into the DNA (Fig. 2) . The potential of our concept based on targeting nuclide-filled liposomes, termed Nuclisome-particles, has recently been evaluated in a number of cell and animal models. Some key results from these investigations, in which we have chosen to use 125 I as Auger-electronemitting radionuclide, will be described in the following sections.
Compound development
In order for the two-step targeting approach to be successful, the radionuclide-labeled compound must fulfill a number of important criteria. Obviously, the compound must display high affinity for DNA, and it is important that it can be Fig. 1 Schematic illustration (adapted from [37] ) of local ionizations (asterisk) along tracks of an alpha particle, a beta particle and electrons from an Auger electron emitter. A beta particle is sparsely ionizing along its track, while an alpha particle is densely ionizing. The cluster of electrons released by an Auger electron-emitting radionuclide produces local dense ionizations Fig. 2 Principle of the Nuclisome two-step-targeting concept. In step 1, Auger electron-emitting radionuclides are delivered to the tumor cell by means of liposomes targeted to structures present on the cell surface. In step 2, the radionuclides are guided to the cell nucleus and exert their DNA-damaging effect encapsulated and retained in liposomes. Further, it is crucial that the compound after cellular uptake of the liposomes is effectively released into the cytoplasm. Finally, it is essential that the compound subsequent to cytoplasm release finds its way and accumulates in the cell nucleus.
In our search for suitable compound candidates to bind nuclides to tumor cell DNA, we have focused our attention on low-molecular weight molecules with an established DNA-binding capacity. Initially, several attempts were made using boronated phenanthridinium and acridine analogs [10] [11] [12] [13] [14] [15] . These were primarily intended for boron neutron capture therapy but the compounds possessed properties that allowed them to serve as precursors for radiolabeling, as well. Although several of the analogs could be satisfactorily loaded into the targeted liposomes, none of the investigated compounds displayed the required ability to reach and accumulate in the nucleus of tumor cells. Further development and characterization of these derivatives were therefore abandoned. With the aim to identify an alternative class of molecules with capability to facilitate DNA delivery of the Auger-electron-emitting radionuclides, we turned our attention to the anthracyclines.
Many anthracyclines can be successfully encapsulated in liposomes, and in particular, liposomal doxorubicin and daunorubicin have been frequently used in studies aiming at both passive [16, 17] and active [18] targeting of tumor cells. Inspired by these studies, we set out to investigate a series of specially designed and synthesized aminobenzyl derivatives of daunorubicin [19] . The synthesized derivatives were mainly substituted at the N-3′ position in the sugar moiety or in the C-13 position in the core structure. Based on the results of the initial tests, three compounds, Comp1-3, were selected for further analysis and characterization [20] .
When tested in iodinated form, all three compounds were found to bind to calf thymus DNA with equal or stronger affinity than that found for the mother compound daunorubicin. A comparison of the determined binding constants and exclusion parameters indicated, however, that Comp1 and Comp2 interacted more favorably with DNA than Comp3 did. Moreover, as probed by laser confocal microscopy, Comp3 showed little, or no, tendency to accumulate in the nucleus of living cells. A similar lack of nuclear staining was observed for cells treated with Comp2. For Comp1, on the other hand, the confocal microscopy images exhibited a fluorescence pattern indicative of nuclear staining. In line with this, cells treated with (Table 1) . 125 I-Comp1 was further characterized in terms of its ability to cause DSB in extracted chromosomal DNA. Based on DNA fragmentation analyses, using pulsedfield gel electrophoresis, it was possible to determine that 
Target specificity
A large number of potential targets, including carcinoembryonic antigen [22] , folic acid receptor [23] , EGF receptor (EGFR) [12] , human epidermal growth factor receptor 2 (HER2) [24] , CD19 [25] , and somatostatin receptors (SSTRs) [26] , have been suggested for targeting liposomes. For the Nuclisome-particles, we have so far chosen to focus on targeting against members of the EGF receptor family. The EGF receptor family consists of the four transmembrane receptors EGFR, HER2, HER3, and HER4 [27] . In normal cells, the receptors are responsible for proliferation and differentiation. However, disturbances in their regulation and signaling pathways can result in malignancies [28, 29] . Many tumor cells are known to express one or several of the EGF family receptors to a degree that far exceeds that found in normal cells. Overexpression of EGFR is found in, for example, the lung, breast, colon, prostate, as well as squamous cell cancer of the head and neck [28] , and overexpression of HER2 is found in, for example, breast, ovarian, and stomach cancers [27] . This overexpression is mainly due to gene amplification and is often associated with tumor progression and poor prognosis [27, 30] . Due to the common overexpression and the link to poor prognosis, we have in our studies performed to date selected EGFR and HER2 as the primary targets for our Nuclisome-particles.
For targeting against EGFR, we have employed the natural ligand EGF as a targeting agent, whereas for targeting against HER2, a single-chain fragment (F5) [31] has been used. In both cases, the targeting agents have been conjugated to the distal end of polyethylene glycol (PEG) in the PEG lipids. The EGF-PEG-lipid and F5-PEG-lipid conjugates have subsequently been incorporated into liposomes composed of DSPC, cholesterol, and DSPE-PEG2000 (see e.g., [32, 33] ). Finally, the liposomes have been loaded with iodinated Comp1 using the pH gradient-driven loading protocol which was first suggested by Mayer et al. [34] .
The receptor specificity of the EGFR-and HER2-targeted Nuclisome-particles has been investigated and verified in two separate in vitro studies. By the use of cellular assays that permitted quantification of the receptor-mediated uptake of the particles, we could confirm that the Nuclisome-particles are indeed taken up by the cultured cells through their interaction with EGFR and HER2, respectively [32, 33] . Importantly, the above studies showed that when the receptors were blocked with an excess amount of free ligand or liposomes were administered without targeting agent, the tumor cell uptake was clearly suppressed.
Receptor specificity was further manifested in an ex vivo human vasculature system (Chandler loop) [32] . In the set-up, fresh human blood from a healthy donor was mixed with cultured human tumor cells, mimicking the circulating tumor cells. EGFR-targeted Nuclisome-particles were added to the loop, and the target specificity was analyzed a few hours after administration. All three parts of the Nuclisome-particles, the targeting agent, the liposome, and the drug, exhibited a 
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Data compiled from Fondell et al. [32] substantial uptake in EGFR-expressing tumor cells while the uptake in white blood cells was minor. The uptake of 125 IComp1 in tumor cells was almost 35 times higher than that in the white blood cells, which leads to a significant difference in the absorbed dose. The results from ex vivo experiments thus clearly demonstrate the potential of Nuclisome-particles to deliver a DNA-binding Auger electron emitter to the circulating tumor cells.
Therapeutic effect in vitro
The in vitro evaluation of the Nuclisome-particles has included confocal microscopy and autoradiography studies to verify that the radiolabeled drug, after cellular uptake of the particles, is set free in the cytoplasm and is able to translocate to the cell nucleus [32, 33] . These studies have been followed up by investigations designed to evaluate the therapeutic effect of the particles. Results of recently reported cell studies indicate a remarkably high tumor cell-killing efficiency of EGFR-targeted Nuclisome-particles as compared to that of EGFR-targeted liposomes loaded with 127 I-labeled Comp1 or the conventional anthracycline doxorubicin [32] . Under the experimental conditions employed, nontargeting liposomes loaded with 127 I-Comp1 or doxorubicin had no discernible inhibitory effect on the growth of cultured tumor cells. It can be noted that nontargeted liposomes containing doxorubicin are presently clinically used for the treatment of Kaposi's sarcoma and breast cancer. The commercially available formulations employ either PEGstabilized (Caelyx/Doxil) or nonstabilized (Myocet) liposomes.
An increased efficacy of doxorubicin-loaded liposomes could, in our studies, be seen by adding EGF as a targeting agent, confirming the previously reported efficacy enhancement achieved with the targeting liposomes [35] . However, EGFR-targeted Nuclisome-particles loaded with the 125 Ilabeled Comp1 were up to five orders of magnitude more effective than EGFR-targeted liposomes loaded with doxorubicin (Table 2) . Importantly, upon replacing 125 I-Comp1 in the targeting Nuclisome-particles with 127 I-Comp1, the growth inhibitory effect was completely lost. It is thus evident that the dramatic effect of the 125 I-Comp1-loaded targeting Nuclisome-particles derives from 125 I solely. Keeping in mind that autoradiography of cells incubated with EGFR-targeted Nuclisome-particles showed that radioactive decays were colocalized with the nuclei of tumor cells Data compiled from Gedda et al. [36] . Mean doses are presented under the assumption of nonfunctional two-step targeting (no HER2 expression), and the distribution of activity in the therapy study follows the biodistribution of HER2-targeting and nontargeting liposomes presented in Fondell et al. [33] [32], it appears plausible that 125 I causes an Auger effect on tumor cell DNA.
A similar high tumor-specific cell-killing potential has been established also for HER2-targeted Nuclisome-particles [33] . Further, data collected verified a dose-response correlation compatible with that expected, following high linear energy transfer irradiation. This finding further supports the suggestion of Nuclisome-particles being able to provide a biological Auger effect.
Therapeutic effect in vivo
The in vivo therapeutic effect of Nuclisome-particles was recently demonstrated in a dose-escalating efficacy study [36] . Ten million HER2-expressing human ovarian cancer cells were injected i. p. in nude mice followed by i. p. administration of HER2-targeted Nuclisome-particles. Different groups received the same amount of Nuclisome-particles but with varying specific radioactivity. The results revealed a clear correlation between the administered radioactivity and the survival of the mice. With HER2-targeting Nuclisomeparticles, a significant increase in survival, as compared to that of untreated control mice, could be seen already at an administered radioactivity corresponding to 0.1 MBq/mouse (Fig. 3) . Further, an increase in administered radioactivity leads to a prolonged survival. At the highest radioactivity administered, 2 MBq/mice, 70% of the mice survived the study, and the majority of these were tumor-free. Dose-dependent survival was not observed for mice treated with Nuclisome-particles lacking HER2-targeting ability.
Notably, neither macroscopic nor microscopic radiotoxic effect in normal tissues was observed. Dosimetric calculations based on previous biodistribution data and assuming nonfunctional two-step targeting in organs not expressing HER2, suggested that mean absorbed doses to normal tissues were low (Table 3 ). According to the calculations, the organ accumulating most Nuclisome-particles, spleen, received merely 0.3 Gy during treatment with 2 MBq/mouse. Since the accumulation of 125 I in spleen was higher than in tumor cells, this finding constitutes further, indirect evidence to support that an Auger effect was achieved in the receptor-targeted tumor cells. More specifically, in the absence of an Auger effect, an absorbed dose of less than 0.3 Gy in tumor cells would not give the dramatic tumor cell eradication and the prolonged survival seen in our study.
Possible clinical applications
The high specificity and remarkable potency make Nuclisomeparticles interesting for several clinical indications. Results obtained to date suggest that treatment with Nuclisomeparticles has the potential to become an effective therapy against metastasizing cancer cells. An important target could be breast cancer, and the large amount of activity delivered per each Nuclisome-receptor interaction opens up for the possibility of treating single tumor cells circulating in the blood. Further, spread tumor cells are most suitable as targets since liposomes have limited penetration in solid tumors. Ovarian cancer with spread tumor cells in peritoneum can be foreseen as another suitable application as demonstrated in the recent animal study. Moreover, by exchanging the targeting agent, Nuclisome-particles could be directed against tumor cells originating from, e.g., prostate and colon cancer, or tailored for the treatment of endocrine tumors.
Worth noting, the choice of Auger-electron-emitting nuclides as active components in the Nuclisome-particles circumvents two of the major drawbacks faced by current protocols for clinical radionuclide therapy. Due to the very local effect, limited to only targeted cells, normal tissue and dose-limiting organs, such as bone marrow, are spared from crossfire from the nuclide. Further, due to the short range of the Auger electrons, the need for special nuclear medicine facilities and patient isolation could be avoided. An example may serve to illustrate the possible benefits of utilizing Auger-electron-emitting nuclides for tumor therapy. A crude estimate suggests that the amount of circulating single tumor cells or micro-metastases in a patient with disseminated disease corresponds to about 1 g. If roughly a thousand decays of 125 I could be generated in the DNA of each cancer cell, the patient would stand a very good chance of being cured. The total radioactivity involved in such a situation corresponds to about 0.1 MBq, which when injected in the body, without attaching to cellular DNA, corresponds to about 5 mSv for the treated patient [4] . This is approximately equal to the yearly background dose received by the average Swede from ionizing radiation.
